NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Financings

NeuroSense Therapeutics Ltd.

Financings

RaiseDate
Private placement of ordinary shares
Announced: US$600,000 · US$0.8 a share
Buyers: Alon Ben-Noon ($200,000); Or Eisenberg ($200,000)
Insiders: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000
Use of proceeds: General corporate purposes ahead of upcoming clinical and regulatory milestones
Apr 28, 2026
Private placement of ordinary shares
Announced: US$500,000 · US$1.5 a share
Use of proceeds: General corporate purposes and working capital
Sep 4, 2025
Private placement of ordinary shares (or ordinary share equivalents) and warrants
Closed: US$5M raised · US$1.25 a share · Warrants at US$1.25 for 60 months
Buyers: Alon Ben-Noon
Insiders: Chief Executive Officer Alon Ben-Noon entered into the definitive agreement to purchase in the private placement alongside a single investor
Use of proceeds: General corporate and working capital purposes
Dec 18, 2024

Read by 6ix AI from the company's releases